IL-4 protects the B-cell lymphoma cell line CH31 from anti-IgM-induced growth arrest and apoptosis: contribution of the PI-3 kinase/AKT pathway.
about
Asparaginase treatment side-effects may be due to genes with homopolymeric Asn codons (Review-Hypothesis)Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanomaExtensive survey of STAT6 expression in a large series of mesenchymal tumors.A p53 axis regulates B cell receptor-triggered, innate immune system-driven B cell clonal expansion.Type I IL-4Rs selectively activate IRS-2 to induce target gene expression in macrophages.Interleukin-4 distinctively modifies responses of germinal centre-like and activated B-cell-like diffuse large B-cell lymphomas to immuno-chemotherapyChronic proliferative dermatitis in Sharpin null mice: development of an autoinflammatory disease in the absence of B and T lymphocytes and IL4/IL13 signaling.STAT6 deficiency ameliorates Graves' disease severity by suppressing thyroid epithelial cell hyperplasiaProgesterone-induced blocking factor differentially regulates trophoblast and tumor invasion by altering matrix metalloproteinase activity.Differential effects of interleukin-13 and interleukin-6 on Jak/STAT signaling and cell viability in pancreatic β-cells.Preferential Langerhans cell differentiation from CD34(+) precursors upon introduction of ABCG2 (BCRP).Insulin receptor substrate 1 expression enhances the sensitivity of 32D cells to chemotherapy-induced cell death.Effects of sotrastaurin, mycophenolic acid and everolimus on human B-lymphocyte function and activation.miR-638 Inhibits immature Sertoli cell growth by indirectly inactivating PI3K/AKT pathway via SPAG1 gene.IL-4 and IL-13 Receptor Signaling From 4PS to Insulin Receptor Substrate 2: There and Back Again, a Historical View.
P2860
Q26801165-C0E8D10B-FB55-47EE-9B45-7EF018180587Q28749278-E5C04F47-395E-4B57-B4AD-0B1481F4E9C0Q33421985-C510B6C6-A25D-473C-AD87-31CCC1F77BD7Q36016499-F64D1DE8-EDCF-48EA-A9BC-EEB0DF40DDE9Q37337400-2955E371-A5AE-4BE4-AFFB-2833BECF7D49Q37389788-A45A9D24-DE4D-409A-BE3E-BF51D6CD1905Q37499617-025B1700-639B-47B5-B83E-1980B8187576Q37603432-24845670-B38C-4194-81BC-2A7AE5CA6E73Q39134048-687EEDAA-4734-4F4F-AB26-5EEE876C14EDQ39178441-234C2829-1400-45DF-8B15-9DF445AEE1F5Q39569136-00394945-77F0-4615-827C-4A58623FA470Q42234701-637B0626-63E3-4798-9EC5-B5302DD59037Q47362322-72DDD582-E536-4F5A-8FB9-E07BB38E77C3Q50098767-872D33EB-5B3D-4585-BA27-F37C14AB046FQ54977051-0EA2DDDD-A6D2-4DB3-845D-AD951ADEFC62
P2860
IL-4 protects the B-cell lymphoma cell line CH31 from anti-IgM-induced growth arrest and apoptosis: contribution of the PI-3 kinase/AKT pathway.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
IL-4 protects the B-cell lymph ...... f the PI-3 kinase/AKT pathway.
@en
type
label
IL-4 protects the B-cell lymph ...... f the PI-3 kinase/AKT pathway.
@en
prefLabel
IL-4 protects the B-cell lymph ...... f the PI-3 kinase/AKT pathway.
@en
P2093
P2860
P356
P1433
P1476
IL-4 protects the B-cell lymph ...... f the PI-3 kinase/AKT pathway.
@en
P2093
Achsah D Keegan
Elena Semenova
Gregory B Carey
P2860
P2888
P304
P356
10.1038/SJ.CR.2007.90
P577
2007-11-01T00:00:00Z
P5875
P6179
1008116073